The most revealing line in Vikram Joshi's public record concerns neither a successful deal nor an elegant piece of science. It concerns failure. In 2007, while studying at Wharton, Joshi won one of the school's first Venture Awards: $10,000 to spend the summer building a company instead of collecting a conventional internship. He later explained what the award had bought him. “It allowed me the freedom and resources to try things and fail.”
The sentence has aged well. Joshi's career has crossed materials engineering, media, point-of-care diagnostics, CRISPR and engineered immune cells. The nouns keep changing. The operating method does not. Find a consequential technology. Learn where it breaks. Translate it into something partners, investors and eventually customers can act upon. Repeat.
Today he is chief business officer at A2 Biotherapeutics in Agoura Hills, California. A2 Bio is developing cell therapies for solid tumors around an idea called Tmod. Its basic proposition can be described in a sentence and can occupy researchers for years: engineer a T cell with an accelerator and a brake. The accelerator recognizes a target on a tumor. The brake recognizes a marker on normal tissue and tells the cell to stand down. In a field defined by the power to kill, the product is also judgment.
“It allowed me the freedom and resources to try things and fail.”Vikram Joshi, on the Wharton Venture Award
The education of an interface thinker
Long before the language of activators and blockers, Joshi studied materials. He earned a bachelor's degree in materials science and engineering at Cornell and a master's in the same discipline at Stanford. A 2001 conference program places him at Cornell presenting work on magnetic, organically modified aluminosilicate nano-objects. It is the sort of title that cheerfully resists dinner conversation. It is also a clue.
Materials science lives at interfaces. A material is valuable not because of what it is in the abstract, but because of how it behaves under pressure, at a boundary, beside another material, or after manufacture has introduced its tiny indignities. That sensibility follows Joshi's later work. His career has been less about one scientific domain than about making sophisticated systems behave usefully in an imperfect world.
Wharton added a second kind of interface: the point where invention meets an organization. Joshi studied healthcare management and entrepreneurship from 2006 to 2008. The venture award arrived after his first year. Its nickname was the anti-internship, a lovely piece of institutional mischief. Instead of borrowing prestige from an established employer, recipients had to make progress on their own ideas and return with something learned.
A laboratory small enough to hold
After business school, Joshi co-founded Proxim Diagnostics. The company's ambition was tactile: a battery-powered immunodiagnostic instrument that could perform important laboratory tests near the patient using whole blood. Central laboratories offer performance but impose distance and delay. Point-of-care devices offer speed but can surrender sensitivity or precision. Proxim wanted the useful parts of both.
Joshi led the company as chief executive for seven years, taking it from product concept toward realization. The details show how naturally his engineering and commercial lives overlapped. He and co-founder Mikhail Briman were named as inventors on work involving carbon-based electrodes modified with graphene platelets. The goal was not graphene for graphene's sake. The patent describes improvements in physical, electrical and biochemical properties, including reproducibility. Glamour fades quickly in diagnostics; reproducibility keeps the lights on.
Proxim's later Profile system paired a handheld instrument with disposable cartridges. The company described uses in emergency departments and settings around the world where rapid results matter and central equipment is not close at hand. On its team page, Joshi framed his aspiration in similarly practical terms: better and cheaper treatments in the hands of healthcare providers around the globe. The romance, if one can call it that, is in distribution.
The mammoth in the room
Joshi eventually moved from a company he had founded to a young CRISPR company built around work from Jennifer Doudna's laboratory. An archived Mammoth Biosciences team page lists him as head of business development. He later became senior vice president. A2 Bio credits his tenure with major partnerships across Mammoth's therapeutic and diagnostic units.
The shift was larger than a change of employer. A diagnostic device has dimensions, cartridges and a screen. A CRISPR platform is a library of biological tools and possibilities. Business development in that setting requires a peculiar bilingualism: enough technical fluency to preserve what makes the science valuable, and enough commercial discipline to decide which applications, collaborators and terms deserve scarce time.
In early 2020, Joshi was thanked for advice and discussions in Mammoth's rapid CRISPR detection protocol. The acknowledgment is modest, as acknowledgments tend to be, but it locates him near the work at a consequential moment. In 2021, when Mammoth announced $195 million in financing, Joshi called it another step in an important journey and placed the emphasis on pride in the team. His public voice is sparse. When it appears, it tends to point away from himself and toward the enterprise.
A logic gate made of living cells
Joshi joined A2 Bio as chief business officer in 2023. By then, the company had moved its Tmod platform into clinical development. The problem it addresses is brutally simple. A therapy aimed at a marker common to both tumor and normal cells may attack both. A2 Bio's approach uses genetic loss in tumor cells as a second piece of information. Its engineered T cells carry an activator that sees a tumor-associated antigen and a blocker that recognizes HLA-A*02 on normal cells. When that protective marker is present, the blocker is intended to restrain the attack. When a tumor has lost it, the activator can proceed.
The Tmod distinction, simplified
This is a simplified account, as it must be. The platform spans autologous therapies made from a patient's cells and allogeneic therapies designed as off-the-shelf products. Patient identification depends on genomic screening for loss of heterozygosity. Manufacturing, trial design, regulation and capital all sit between a clever circuit and a useful therapy. The chief business officer works among those dependencies, where no single discipline gets the final word.
A2 Bio closed an $80 million Series C in January 2025, backed by a group that included The Column Group and Samsara BioCapital. The company said the money would support three clinical programs and its broader CAR-T pipeline. In June, it dosed the first patient in DENALI-1, a Phase 1/2 study of A2B395, an allogeneic candidate for solid tumors expressing EGFR. Further regulatory and clinical updates followed across the pipeline in 2026.
Materials research at Cornell appears in the MRS Spring Meeting program.
An inaugural Wharton Venture Award makes room for a summer of building and learning.
Proxim Diagnostics begins its attempt to put central-lab performance into a handheld system.
At Mammoth, Joshi moves from head of business development to senior vice president.
He joins A2 Biotherapeutics as chief business officer.
A2 Bio finances three clinical programs and advances its first allogeneic Tmod candidate into human testing.
The discipline behind the deal
There is a temptation to narrate this as a smooth ascent: engineer becomes founder, founder becomes dealmaker, dealmaker becomes executive. The evidence suggests something more interesting. Joshi has kept returning to technologies that are difficult to make discriminating enough. The handheld test must be fast without becoming sloppy. The CRISPR partnership must expand a platform without confusing its purpose. The engineered cell must attack without forgetting what to spare.
In each case, the commercial question is inseparable from the technical one. Who is the product for? What evidence changes a partner's mind? Which capability belongs inside the company, and which can be borrowed through collaboration? A business-development executive does not answer those questions alone. The value lies in giving scientists, operators, investors and partners a common object to reason about.
That may explain why the old venture-award reflection remains the best key to Joshi's career. Failure was not presented as a badge or a dramatic ruin. It was part of a system that also demanded progress and learning. The distinction matters. Permission to fail without an obligation to learn is merely indulgence. Learning without permission to fail produces timid experiments. Company-building needs both.
Joshi's work at A2 Bio is now attached to milestones more public than a summer venture report: financing, regulatory designations, patients enrolled, clinical findings. Yet the original bargain survives. Run the experiment. Respect the result. Make the next decision with greater precision. For a career built around boundaries, it is a fitting logic gate of its own.